Key Takeaways:
Law firm Kahn Swick & Foti announced an investigation into the proposed sale of KalVista Pharmaceuticals Inc. (NasdaqGM: KALV) to Chiesi Group for $27.00 per share.
"KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company," the law firm said in a statement Tuesday.
The $27.00 per share cash offer was part of a definitive agreement announced on April 29. In the days following the announcement, analysts at Stifel, HC Wainwright, and Leerink all downgraded KalVista's stock to Hold or Neutral and adjusted their price targets to $27, directly aligning with the acquisition price.
The investigation highlights potential shareholder concern over the deal's valuation. As the transaction is structured as a tender offer, the probe adds a layer of complexity that could influence shareholder participation and the deal's timeline.
The law firm, which includes former Louisiana Attorney General Charles C. Foti, Jr., is soliciting contact from KalVista shareholders who believe the transaction undervalues the company. The firm noted that time may be of the essence due to the tender offer structure.
KalVista Pharmaceuticals is a pharmaceutical company focused on treatments for hereditary angioedema. The acquisition by the Italian firm Chiesi Group is intended to expand Chiesi's global rare disease portfolio.
Shares of KalVista traded at $26.76 on Tuesday, just below the $27.00 offer price, suggesting the market is pricing in a high probability of the deal closing but with little room for a competing bid.
The investigation could create pressure for a higher acquisition price, potentially benefiting shareholders. Conversely, it could introduce legal complications that delay or derail the deal, risking the collapse of the acquisition premium.
This article is for informational purposes only and does not constitute investment advice.
